Pfizer, U.S. health officials to discuss COVID boosters on Monday -company
Reuters
Published Jul 11, 2021 01:00PM ET
Updated Jul 11, 2021 07:30PM ET
WASHINGTON (Reuters) - COVID-19 vaccine maker Pfizer Inc (NYSE:PFE) will meet with federal health officials as soon as Monday to discuss the need for a booster dose of the coronavirus vaccine as it prepares to seek authorization, the company said on Sunday.
The meeting comes days after the drugmaker and its partner BioNTech SE (NASDAQ:BNTX) announced plans to seek U.S. and European regulatory approval for a third dose of their COVID-19 shot amid the spread of variants and data they said showed heightened risk of infection six months after initial inoculation.
That push prompted a quick response from the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention, saying Americans do not need a booster right now.
On Monday, Pfizer is scheduled to meet with representatives of the FDA, a company spokesperson said. The meeting was first reported by the Washington Post.
Representatives for the U.S. Department of Health and Human Services did not immediately respond to a request for comment.
Anthony Fauci, President Joe Biden’s chief medical adviser who also directs the National Institute of Allergy and Infectious Diseases, as well as the heads of the National Institutes of Health and the CDC were also among those invited to the briefing, which could move to another day, according to the Post's report.
Fauci, in several television interviews on Sunday, said U.S. health officials were not dismissing the possible future need for boosters -- especially as breakthrough infections among those who have been vaccinated have emerged -- but that more data is needed for any formal recommendation.
"There's a lot of dynamic things going on right now," he told ABC News' "This Week" program.
"There are studies being done now ongoing as we speak about looking at the feasibility about if and when we should be boosting people... there's a lot of work going on to examine this in real time," he added on CNN's "State of the Union."
Despite the FDA and CDC's statement, "that doesn't mean that we're not very, very actively following and gathering all of this information to see if and when we might need it and if and when we do, we'll have everything in place to do it."
U.S. health officials are still struggling to get people in some areas to receive their initial inoculations as the highly contagious Delta variant has grown to be the nation's dominant strain, with COVID-19 cases rising mostly among the unvaccinated.
European officials has also said vaccines currently seem protective against variants. Canada has also said it is monitoring variants and the possible need for boosters.
Get The News You Want
While some scientists have also questioned the need for booster shots, others have said they could be beneficial for the elderly and other vulnerable populations, although it is unclear when they would be needed.
Some public health experts have also expressed concern that authorizing boosters in wealthy developed nations while other countries are still struggling against initial inoculations will further exacerbate vaccine inequity.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.